State of Wisconsin Investment Board
CLDX icon

State of Wisconsin Investment Board’s Celldex Therapeutics CLDX Stock Holding History

State of Wisconsin Investment Board’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.08M Sell
34,109
-3,957
-10% -$108K ﹤0.01% 1655
2025
Q4 		$1.03M Sell
38,066
-6,693
-15% -$176K ﹤0.01% 1665
2025
Q3 		$1.16M Sell
44,759
-39,967
-47% -$926K ﹤0.01% 1559
2025
Q2 		$1.72M Buy
84,726
+49,871
+143% +$971K ﹤0.01% 1367
2025
Q1 		$633K Sell
34,855
-5,458
-14% -$122K ﹤0.01% 1656
2024
Q4 		$1.02M Sell
40,313
-1,047
-3% -$28.4K ﹤0.01% 1521
2024
Q3 		$1.41M Buy
41,360
+4,590
+12% +$175K ﹤0.01% 1450
2024
Q2 		$1.36M Buy
36,770
+538
+1% +$20.3K ﹤0.01% 1450
2024
Q1 		$1.52M Sell
36,232
-4,286
-11% -$176K ﹤0.01% 1318
2023
Q4 		$1.61M Buy
40,518
+8,569
+27% +$252K ﹤0.01% 1282
2023
Q3 		$879K Sell
31,949
-1,238
-4% -$38.8K ﹤0.01% 1446
2023
Q2 		$1.13M Sell
33,187
-4,678
-12% -$158K ﹤0.01% 1429
2023
Q1 		$1.36M Buy
37,865
+299
+0.8% +$12.9K ﹤0.01% 1398
2022
Q4 		$1.67M Sell
37,566
-414
-1% -$14.8K 0.01% 1362
2022
Q3 		$1.07M Sell
37,980
-2,319
-6% -$71.1K ﹤0.01% 1516
2022
Q2 		$1.09M Sell
40,299
-21,301
-35% -$619K ﹤0.01% 1598
2022
Q1 		$2.1M Buy
61,600
+10,900
+21% +$348K ﹤0.01% 1481
2021
Q4 		$1.96M Hold
50,700
– – ﹤0.01% 1284
2021
Q3 		$2.74M Buy
50,700
+1,000
+2% +$46.9K 0.01% 1212
2021
Q2 		$1.66M Buy
+49,700
New +$1.36M ﹤0.01% 1328
2018
Q3 		– Sell
-28,814
Closed -$218K – 1545
2018
Q2 		$218K Sell
28,814
-20,120
-41% -$269K ﹤0.01% 1420
2018
Q1 		$1.71M Sell
48,934
-6,733
-12% -$261K ﹤0.01% 994
2017
Q4 		$2.37M Hold
55,667
– – 0.01% 955
2017
Q3 		$2.39M Hold
55,667
– – 0.01% 950
2017
Q2 		$2.06M Buy
55,667
+5,667
+11% +$251K 0.01% 944
2017
Q1 		$2.71M Buy
50,000
+33,676
+206% +$1.75M 0.01% 886
2016
Q4 		$867K Buy
+16,324
New +$929K ﹤0.01% 1212

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

State of Wisconsin Investment Board's CLDX Position: Q1 2026 in Review

State of Wisconsin Investment Board reduced its Celldex Therapeutics (CLDX) stake by 10% in Q1 2026, selling an estimated $108K and leaving 34,109 shares worth $1.08M. The position accounts for ﹤0.01% of the portfolio, ranked #1655.

State of Wisconsin Investment Board first reported a position in CLDX in Q4 2016 and has held it in 27 quarters since. The position peaked at $2.74M in Q3 2021. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

  • State of Wisconsin Investment Board held 34,109 shares of Celldex Therapeutics worth $1.08M as of Q1 2026.
  • State of Wisconsin Investment Board sold 3,957 Celldex Therapeutics shares in Q1 2026, an estimated $108K.
  • Celldex Therapeutics made up ﹤0.01% of State of Wisconsin Investment Board's portfolio in Q1 2026, its #1655 holding.
  • State of Wisconsin Investment Board first reported a position in Celldex Therapeutics in Q4 2016 and has held it in 27 quarters since.
  • State of Wisconsin Investment Board's Celldex Therapeutics position peaked at $2.74M in Q3 2021.
  • 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on State of Wisconsin Investment Board's 13F filing for Q1 2026, filed 15 May 2026.